European biotech financing gravitates to Benelux
This article was originally published in Scrip
European entrepreneurs looking to establish new biotech companies are more likely to raise the funds they need by looking to the Benelux rather than the traditional powerhouses of the UK and Germany. Dr Edwin Moses, chief executive officer and chairman of Ablynx, the Ghent-based camelid antibody company and a serial entrepreneur, doubts whether start-ups can raise the hundreds of millions of Euros necessary to discover and develop new medicines in any market other than those emerging in the Benelux countries.
You may also be interested in...
Charting the executive gender mix across 384 companies from mid-2014 to mid-2019 demonstrates that C-suite gender balance in pharma is moving towards a point that more closely reflects its total workforce, but that progress has been slow and that there is a long road to travel before the transformation is complete.
With gender diversity only slowly increasing in biopharma c-suites, Scrip spoke to executives from five companies about the importance of change.
In a flat month, the market value of big pharma changed little overall. But the balance of power in immuno-oncology did shift significantly.